Who
Ingmar Bruns
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Zentalis Pharmaceuticals; Chief Medical Officer, Trillium Therapeutics.
In numbers
- Trades disclosed
- 12
- Buys
- 1
- Sells
- 2
- Bought
- $46K
- Sold
- $16K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 17 Nov 2021
- Last trade
- 30 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 1 Oct 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $21K9,727 at $2.18 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $802335 at $2.39 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $801335 at $2.39 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,1972,962 at $2.43 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $7,1982,962 at $2.43 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —365,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —365,000 at $0.00 | filing |
| 6 Feb 2025filed 12 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $46K20,000 at $2.28 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,629 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,629 at $0.00 | filing |
| 2 Dec 2024filed 3 Dec 2024 | ZNTL Zentalis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —712,650 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —400,000 at $0.00 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name Ingmar Bruns; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.